


Amyloid β -Protein Dimers Isolated Directly from Alzheimer Brains Impair Synaptic Plasticity and Memory

Ganesh M. Shankar, Shaomin Li, Tapan H. Mehta, Amaya Garcia-Munoz, Nina E. Shepardson, Imelda Smith, Francesca M. Brett, Michael A. Farrell, Michael J. Rowan, Cynthia A. Lemere, Ciaran M. Regan, Dominic M. Walsh, Bernardo L. Sabatini and Dennis J. Selkoe

SUPPLEMENTAL FIGURE LEGENDS


Supplemental Figure 1. AD soluble (TBS) brain extract does not affect baseline synaptic transmission or presynaptic release probability, but causes dose dependent LTP inhibition. **a.** After recording fEPSPs for 10 min, 500 μ L TBS Veh, Con TBS extract or AD TBS extract were added to the ACSF bath (time indicated by arrow). fEPSPs were recorded for an additional 70 min following this wash-in. **b.** Paired pulse facilitation (PPF) was calculated from the slope of the two fEPSPs resulting from an inter-stimulus interval of 50 msec. ANOVA was performed on average PPF 5 min prior to HFS (Pre-HFS) or for 55–60 min after HFS (post-HFS) from slices exposed to TBS Veh, Con TBS or AD TBS. **c.** Post-tetanic potentiation (PTP) calculated from fEPSPs recorded 5 min following HFS. **d.** The LTP inhibition by A β in the soluble (TBS) extract of AD cortex is dose dependent. Data are plotted as percentages of optimal LTP (i.e., that obtained in 500 μ L plain TBS) measured at 50–60 min following HFS. Each dose is indicated on the abscissa as the volume of AD TBS extract that was added to a volume of plain TBS to yield a final sample volume of 500 μ L. In the case of the 500 μ L and 1000 μ L samples, the AD TBS extract was added straight. Dashed line indicates approximation of IC₅₀ value for AD TBS, which corresponds to a final A β concentration of \sim 7 pM in the slice perfusate. **e.** TBS cortical extracts from humans with confirmed frontotemporal dementia (FTD, Fig. 1) or dementia with Lewy bodies (DLB, Fig. 1) do not inhibit LTP induction. Summary data for LTP induction in slices treated with 500 μ L TBS extracts of brains with either FTD (green) or DLB (purple). For comparison, LTP data from Fig. 2b (means \pm SEM) for Con TBS (blue) and AD TBS (red) are shown as horizontal bars. **f.** The mGluR5 antagonist SIB1757 does not block the effect of AD TBS on LTP. Summary LTP data for co-administration of 3 μ M SIB1757 with 500 μ L AD TBS (n=5 slices) for 20 minutes prior to the HFS (indicated by arrow). For comparison, LTP data from Fig. 2b (means \pm SEM) for Con TBS (blue) and AD TBS (red) are shown as horizontal bars.

Supplemental Figure 1




Supplemental Figure 2. N-terminal antibodies recognize A β dimers and neutralize their effects on synaptic plasticity more effectively than antibodies targeting the A β mid-region. **a.** AD TBS and Con TBS was first IP'd with 3 μ g/mL of either 3D6 (N-term), 4G8 (mid) or 2G3/21F12 (C-term) A β antibodies (see text) and probed with A β antibodies 6E10 plus 266. The sup after this first IP was then IP'ed with polyclonal A β antibody R1282 (2nd IP) and probed with 6E10 plus 266 to detect remaining A β species. **b.** Summary LTD data for co-administration of AD TBS with 3 μ g/mL of N-terminal (+N-term, green) or C-terminal (+C-term, black) A β antibodies. LTD data (means \pm SEM) for Con TBS (blue) and AD TBS (red) are shown as horizontal bars. **c.** Summary LTD data (means \pm SEM) for co-administration of AD TBS with 3 μ g/mL 4G8 (+4G8, black, n=3 slices) for 20 min prior to LFS (grey bar). LTD data for Con TBS (blue) and AD TBS (red) from Fig. 2e are shown as horizontal bars. **d.** Summary LTP data (means \pm SEM) for co-administration of AD TBS with 3 μ g/mL 3D6 (N-term, black, n=5 slices) or 2G3/21F12 (C-term, green, n=5 slices) for 20 min prior to HFS (arrow). LTD data for Con TBS (blue) and AD TBS (red) are shown as horizontal bars.

Supplemental Figure 2




Supplemental Figure 3. Introduction of AD TBS at either 0 h or 6 h following training in a passive avoidance paradigm does not significantly impair the recall of this learned behavior. **a.** WB of three sequential IP's of the TBS extract (AD TBS). AD TBS-ID is the TBS supernatant remaining after the third immunodepletion (ID3). AD TBS (red) or AD TBS-ID (immunodepleted, black) was introduced i.c.v. into the lateral ventricle at either **(b)** 3 h, or **(c)** 0 h, or **(d)** 6 h following training. No significant differences between the two treatment groups were observed in locomotion scores (left) or rearing scores (middle) measured at 48 or 24 h prior to training. Furthermore, the escape latency (right) was not significantly different at 24 h or 48 h post-training when comparing rats receiving AD TBS (n=5 and 5 rats for injections at 0 h and 6 h) or AD TBS-ID (also n=5 and 5). While the escape latency was not significantly different at 24 h post-training between rats treated at 3 h with AD TBS or AD TBS-ID (b, right), a significant difference was observed at 48 h (see Fig. 2h).

Supplemental Figure 3




Supplemental Figure 4. Soluble A β from AD brain decreases dendritic spine density through a NMDAR-dependent pathway. **a.** Representative images of apical dendrites from 5 DIV pyramidal cells in organotypic hippocampal slices cultured for an additional 10 days in sham condition or with SEC-enriched TBS extract from AD brain (AD TBS-SEC) or from Con brain (Con TBS-SEC). Scale bar = 5 μ m. **b.** Summary data for spine length. **c.** Representative images of slices treated with 500 μ M MCPG or 20 μ M CPP in the absence (sham) or presence of AD TBS-SEC.

Supplemental Figure 4



Supplemental Figure 5. Mass spectrometric confirmation of human A β in the 8 kDa dimer band after IP of the GuHCl extract of an AD brain. **a.** Insoluble (GuHCl) extract of AD brain was IP'ed with either 2G3 or 21F12 (or R1282 as a control), and all 3 precipitates were probed with 21F12. 21F12 detects an A $\beta_{40/42}$ heterodimer (arrow) in the 2G3 IP but detects far more A β dimers in the 21F12 IP, representing A $\beta_{42/42}$ homodimers. **b.** GuHCl extracts of AD or control brain were IP'ed with a combination of 2G3, 21F12 and 4G8. WB with 4G8 (left panel) and silver staining (right panel) reveal bands in AD but not Con brain that correspond to the sizes of A β monomer (M) and dimer (D). Bands identified as A β monomer and dimer by WB and silver stain were digested with trypsin and the resulting peptides analyzed by LC-MS/MS. Analysis of the dimer band provided the sequences of: **c.** residues 17–28; **d.** residues 29–40; and **e.** residues 29–40 with an oxidized methionine at position 35 (a modification previously described in A β from AD cortex¹). The predicted peptide fragments are displayed vertically on the left and the observed mass-to-charge ratios are displayed horizontally on the right. Analysis of the monomer band provided the same peptide sequences (not shown). We did not recover the N-terminal tryptic fragment of A β (residues 1–16) from either the 4 or 8 kDa bands, but IP with Asp-1 specific N-terminal A β antibodies confirmed that these bands both contain A β beginning at Asp-1 (e.g., see Supp. Fig. 2a).

Supplemental Figure 5




Supplemental Figure 6. A β in AD TBS extracts can be purified and resolved as oligomer- and monomer-rich fractions by IP followed by SEC. AD TBS (top) or Con TBS (bottom) was IP'ed with 3D6 (3 μ g/mL), eluted with sample buffer containing 4% LDS and subjected to SEC. SEC of AD TBS without IP (top left) reveals that A β monomers and dimers elute in fraction 4, which corresponds to the column void volume. This is detected by A β C-terminal antibodies 2G3/21F12. Immunodepleted AD TBS (following IP with 3D6) reveals a similar pattern of background bands detected by WB (top center). SEC of the IP (top right) resolves A β dimers (fractions 7/8) from monomers (fractions 9/10), as detected by 2G3/21F12 and 4G8. Fractions from the IP-SEC sample also contain intact immunoglobulin (IgG), and heavy chain (H) and light chain (L) fragments contributed by the immunoprecipitating antibody, as detected under these non-reducing conditions. As seen here and also by silver stain (not shown), the A β -containing fractions following IP-SEC (top right) contain less background protein compared to the starting AD TBS extract (top left). Comparison of AD TBS and Con TBS blots reveals that the only novel species are the 4 and 8 kDa bands that exist only in AD TBS (not Con TBS, lower panels) and represent A β monomer and dimer, respectively.


Supplemental Figure 7. Amyloid cores enriched from human AD cortex consist of dimers that are not readily released under physiologic conditions. **a.** Amyloid cores were prepared from AD brain tissue (100 mg wet wt) through sequential extractions with TBS and 2% SDS (as described in Methods and Figs. 6a, b). IP/WB analyses of wash supernatants reveal no additional soluble A β species are liberated from the core prep by three final TBS washes after 4 sequential SDS washes. **b.** Amyloid cores remaining after the 7 sequential washes in (a) were subjected to a variety of incubation conditions to attempt the release of soluble A β species. Sample 1 was cores prepared from 100 mg brain wet wt as in (a) and probed without further incubation. Samples 2–5 were cores prepared from 100 mg (samples 3–5) or 500 mg (sample 2) and then all incubated at 37°C for 24 hr. Samples 2 and 3 were incubated in 1% BSA in TBS (BSA was used to prevent non-specific loss of A β on the wall of the siliconized tube during incubation). Sample 4 was sonicated for 1 min to increase amyloid core surface area then incubated in 1% BSA in TBS. Sample 5 was incubated in Con TBS to determine whether any soluble proteins in human brain extract could liberate A β from the cores. IP/WB analysis of the post-500 g supernatants (bottom panel) and formic acid (FA) extracted pellets (top panel) reveal A β dimers in the FA extracts of the remaining core pellet, but no soluble A β released into the supernatant by these various treatments.

Supplemental Figure 7

a



b



Supplemental Table 1. a. Clinical and histopathological information on brain samples used for analysis in Fig. 1a. **b.** Clinical and histopathological information on brain samples used for analysis in Fig. 2a. Total A β levels measured by ELISA in a subset of cases were 1.93 to 2.34 nmol A β /g brain tissue in the insoluble extracts and 0.04 to 1.44 pmol A β /g brain tissue in the soluble extracts of AD cortex, in range with previous reports^{2,3}.

a

| Case ID | Age | Clinical presentation | Neuropathological diagnosis |
|---------|-----|---|--|
| DS | 60 | Down syndrome, AD | AD |
| DLB | 74 | Possible CJD | Dementia with Lewy bodies |
| PCD | 64 | Recent onset of confusion and agitation | Paraneoplastic cerebellar degeneration |
| AD 1 | 73 | Dementia | AD |
| MID 1 | 75 | Recent onset of confusion | Stroke |
| AD 2 | 68 | Dementia | AD |
| P-AD | 78 | Normal pressure hydrocephalus | AD |
| FTD | 50 | Frontotemporal dementia | Frontotemporal dementia |
| MID 2 | 69 | Dementia | Multi-infarct dementia |
| AD 3 | 85 | Dementia | AD |

b

| Case ID | Age | Clinical presentation | Neuropathological diagnosis |
|---------|-----|---------------------------------------|---------------------------------|
| Con 1 | 75 | Neurologically normal | Colloid cyst of third ventricle |
| Con 2 | 70 | atypical dementia, possible AD or FTD | FTD |
| Con 3 | 52 | Neurologically normal | Ventriculomegaly |
| AD 4 | 81 | AD | AD |
| AD 5 | 80 | AD | AD |
| AD 6 | 78 | AD | AD |
| AD 7 | 82 | AD | AD |

SUPPLEMENTARY METHODS

Hippocampal slice preparation for electrophysiology recording. Mice (C57BL/6 x 129, 5-8 wk old) were sacrificed after anesthesia with Isofen. The brain was quickly removed and submerged in ice-cold, oxygenated, sucrose-replaced artificial cerebrospinal fluid (ACSF) cutting solution (all in mM): 206 sucrose, 2 KCl, 2 MgSO₄, 1.25 NaH₂PO₄, 1 CaCl₂, 1 MgCl₂, 26 NaHCO₃, 10 D-glucose, pH 7.4, 315 mOsm. Transverse slices (350 μm thickness) from the middle portion of each hippocampus were cut with a Vibroslicer. After dissection, slices were incubated in ACSF that contained (all in mM): 124 NaCl, 2 KCl, 2 MgSO₄, 1.25 NaH₂PO₄, 2 CaCl₂, 26 NaHCO₃, 10 D-glucose, pH 7.4, 310 mOsm, in which buffer they were allowed to recover for at least 90 min before recording. A single slice was then transferred to the recording chamber and submerged beneath a continuous ACSF perfusate saturated with 95% O₂ and 5% CO₂. Slices were incubated in the recording chamber for 20 min before stimulation at RT (~26°C).

Dendritic spine density analysis. The apical dendrites of pyramidal cells in organotypic hippocampal slices were prepared, treated, imaged and analyzed as described⁴. Briefly, 2 days after organotypic hippocampal slices were prepared from postnatal day 5 (P5) - P7 Sprague-Dawley rats, the slices were biolistically transfected with eGFP-N1 (Clontech, Cambridge, UK). After an additional 3 d of culturing, the various reported treatments were performed for an additional 10 d. All Aβ containing SEC fractions from AD TBS (AD TBS-SEC) and the corresponding fractions from Con TBS (Con TBS-SEC) were pooled separately and lyophilized prior to addition to the culture medium of organotypic hippocampal slice preparations. For treatment with Con TBS-SEC or AD TBS-SEC 350 μL lyophilized SEC fractions of the human brain TBS extract were reconstituted in 3 mL slice culture medium (SCM). 750 μL of this prep were applied to each insert in a 6-well plate. Either D-CPP (20 μM) or (R/S)-MCPG (500 μM) were added to sham or AD TBS-gf treated slices. For treatment with the GuHCl extract SEC fractions, a 450 μL lyophilized fraction was reconstituted in 4.5 mL SCM, of which 750 μL were added to each insert. The media were changed with fresh medium containing these treatments every 2-3 d. At the end of the 10-day treatment, live-cell imaging was performed on the inserts after submerging in ACSF. Apical dendrites were imaged by 2-photon laser scanning microscopy using a 5x zoom corresponding to 42 μm x 42 μm. Analysis on the acquired images was performed blinded to treatment using custom software designed in Matlab. Statistical analyses were performed using Igor Pro (Wavemetrics, Lake Oswego, OR).

Passive Avoidance Conditioning. Passive avoidance training was performed as described previously⁵ (see Supplemental Methods). Wistar rats were obtained from the Biomedical Facility at University College Dublin, and all procedures were conducted in accordance with animal welfare guidelines of the Department of Health and Children (Republic of Ireland). Animals were cannulated at P70 and handled for 6 days prior to training at P80. Weight was measured and behavior was assessed in an open-field apparatus for 5 min periods at 48 and 24 h before training. Locomotion, rearing, grooming, piloerection, defecation and posture were studied to assess post-surgical alterations in behavior. Animals were trained in a single-trial, step-through, light-dark passive avoidance paradigm. The training apparatus chamber was divided into two

compartments, separated by a central shutter that contained a small opening. The smaller of the compartments contained a low-power illumination source; the larger compartment was not illuminated. The floor in the dark compartment consisted of a grid of 16 horizontal stainless-steel bars. A current generator supplied 0.75 mA to the floor, which was scrambled once every 0.5s across the 16 bars. A resistance range of 40–60 mΩ was calculated for a control group of rats (250–350 g), and the apparatus was calibrated accordingly. On the day of training, animals were placed facing the rear of the light compartment of the apparatus, immediately after spontaneous behavior was assessed. The timer was started once the animal completely turned to face the front of the chamber. Latency to enter the dark chamber was recorded (usually <20 s). After the animal completely entered the dark compartment a foot shock was administered to the animal, at which point the subject immediately returned to the light compartment. Animals were then returned to their home cages. At 0, 3, or 6h following this training session, 5 μL soluble human cortical extract was introduced i.c.v. through the cannula at 1μL/min. Recall of the passive avoidance conditioning was evaluated 24 and 48 h post-training by recording the latency to enter the dark chamber, with a criterion time of 300s. Data from the passive avoidance studies were analyzed by ANOVA followed by the Bonferroni post hoc test.

IP-SEC. TBS extracts of AD or control cortex were immunoprecipitated with 3D6 (3 μg/mL), 15 μL PAS and 15 μL PGA. After the beads were washed, the immunoprecipitates were eluted with 10 μL 4% LDS sample buffer, heated at 65°C for 5 min and centrifuged at 14,000 rpm for 5 min. The supernate was transferred to 500 μL TBS and subjected to SEC as described above.

Quantification of Aβ in brain extract. Aβ levels in the brain extract were analyzed by sandwich enzyme-linked immunosorbent assay (ELISA) as described previously⁶. Briefly, 2G3 and 21F12 was used to capture Aβ₄₀ and Aβ₄₂, respectively. Following capture, biotinylated 3D6 or biotinylated 4G8 was used to quantify TBS or GuHCl extracted Aβ, respectively.

Mass spec methods. Mass spectrometry experiments were performed at the Taplin Biological Mass Spectrometry Facility at Harvard Medical School. Gel bands containing Aβ samples were digested with trypsin and then analyzed by nanoscale microcapillary liquid chromatography coupled to tandem mass spectrometry as described⁷.

Production & characterization of cross-linked synthetic dimers. Aβ₁₋₄₀S26C was synthesized by the Biopolymer Laboratory at UCLA Medical School and the correct sequence and purity confirmed by amino acid analysis, reverse-phase HPLC and mass spectrometry. Aβ dimers were generated by atmospheric oxidation of a 20 μM solution of Aβ₁₋₄₀S26C in 20 mM ammonium bicarbonate, pH 8.0, for 4 days at room temperature. To facilitate disassembly of aggregates formed during the oxidation reaction, the peptide solution was lyophilized and subsequently incubated in 5 M GuHCl, Tris-HCl, pH 8.0, for 4 hr. Disulfide cross-linked Aβ dimers were isolated from unreacted monomer and higher aggregates by size exclusion chromatography. Briefly, two Superdex 75 10/30 HR columns were linked in series and eluted with 50 mM

ammonium acetate, pH 8.5 at a flow rate of 0.5 ml/min. Fractions (0.5 ml) were collected, and an aliquot of each was electrophoresed on 16% tris-tricine polyacrylamide gels and detected by silver staining. Fractions found to contain exclusively dimeric A β were pooled and the peptide content determined by comparison to known standards. Samples were stored at -80°C until used.

Isolation of amyloid cores. The pellet resulting from spinning the TBS homogenate at 175,000 g for 30 min (TBS start) was resuspended in 150 μ L 2% SDS per 100 mg starting brain wet weight, boiled at 100°C for 5 min, and centrifuged at 10,000g for 5 min. The supernatant was collected (SDS Wash 1) and the pellet was extracted similarly with SDS an additional 3 times (SDS Washes 2-4). The remaining pellet was resuspended in 150 μ L TBS per 100 mg starting brain wet weight and centrifuged at 500 g for 5 min. The supernatant was collected (TBS Wash 1) and the pellet was washed with TBS an additional two times (TBS Wash 2-3). The resulting washed core prep (following a final centrifugation at 500 g for 5 min) was incubated with 10 μ L 88% formic acid per 100 mg starting brain weight at RT for 2 hr. This sample was neutralized with 2.6 vol 10 N NaOH prior to IP/WB analysis or treatment of acute hippocampal slices. Intact cores (following the final TBS wash) were centrifuged at 500 g and resuspended in 0.2% Congo red for visualization by brightfield and polarized microscopy.

REFERENCES

1. Naslund, J. et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. *Proc Natl Acad Sci U S A* **91**, 8378-82 (1994).
2. Lue, L.F. et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am J Pathol* **155**, 853-62 (1999).
3. Naslund, J. et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. *Jama* **283**, 1571-7 (2000).
4. Shankar, G.M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J Neurosci* **27**, 2866-75 (2007).
5. Fox, G.B., O'Connell, A.W., Murphy, K.J. & Regan, C.M. Memory consolidation induces a transient and time-dependent increase in the frequency of neural cell adhesion molecule polysialylated cells in the adult rat hippocampus. *J Neurochem* **65**, 2796-9 (1995).
6. Sun, X. et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. *Neurosci Lett* **321**, 61-4 (2002).
7. Haas, W. et al. Optimization and use of peptide mass measurement accuracy in shotgun proteomics. *Mol Cell Proteomics* **5**, 1326-37 (2006).